BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7936750)

  • 1. New concepts in the diagnosis and prognosis of endometrial carcinoma.
    Sasano H; Watanabe K; Ito K; Sato S; Yajima A
    Pathol Annu; 1994; 29 ( Pt 2)():31-49. PubMed ID: 7936750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theories of endometrial carcinogenesis: a multidisciplinary approach.
    Sherman ME
    Mod Pathol; 2000 Mar; 13(3):295-308. PubMed ID: 10757340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
    Xue F; Jiao S; Zhao F
    Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus.
    Jiko K; Sasano H; Ito K; Ozawa N; Sato S; Yajima A
    Anticancer Res; 1993; 13(2):305-10. PubMed ID: 8517643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic factors in endometrial carcinoma].
    Ivanov S; Ivanov S
    Akush Ginekol (Sofiia); 1999; 38(3):16-8. PubMed ID: 10734671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of phosphatase and tensin homolog, beta-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations.
    Norimatsu Y; Miyamoto M; Kobayashi TK; Moriya T; Shimizu K; Yanoh K; Tsukayama C; Miyake Y; Ohno E
    Cancer; 2008 Jun; 114(3):155-64. PubMed ID: 18431720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia.
    Espindola D; Kennedy KA; Fischer EG
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):717-37, ix. PubMed ID: 18061866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between NDRG1 and PTEN expression in endometrial carcinoma.
    Chen J; Li S; Yang Z; Lu G; Hu H
    Cancer Sci; 2008 Apr; 99(4):706-10. PubMed ID: 18377423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma.
    Vaskivuo TE; Stenbäck F; Tapanainen JS
    Cancer; 2002 Oct; 95(7):1463-71. PubMed ID: 12237915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in the study of oncogenes and tumor suppressor genes in endometrial carcinoma].
    Xue FX; Zhu YX; Jiao SZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):559-62. PubMed ID: 7835134
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma.
    Ito K; Sasano H; Matsunaga G; Sato S; Yajima A; Nasim S; Garret CT
    J Pathol; 1997 Nov; 183(3):318-24. PubMed ID: 9422988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 and p53 expressions in endometrial cancer.
    Jeon YT; Kang S; Kang DH; Yoo KY; Park IA; Bang YJ; Kim JW; Park NH; Kang SB; Lee HP; Song YS
    Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1538-42. PubMed ID: 15342458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
    Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Sakamoto A; Sakamoto T; Maruyama H; Sato S; Mizunuma H; Smith SK
    Clin Cancer Res; 2003 Apr; 9(4):1361-9. PubMed ID: 12684405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma.
    Pijnenborg JM; Romano A; Dam-de Veen GC; Dunselman GA; Fischer DC; Groothuis PG; Kieback DG
    J Pathol; 2005 Apr; 205(5):597-605. PubMed ID: 15726651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular genetic and statistical approach for the diagnosis of dual-site cancers.
    Brinkmann D; Ryan A; Ayhan A; McCluggage WG; Feakins R; Santibanez-Koref MF; Mein CA; Gayther SA; Jacobs IJ
    J Natl Cancer Inst; 2004 Oct; 96(19):1441-6. PubMed ID: 15467033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD10 immunostaining distinguishes atypical polypoid adenomyofibroma (atypical polypoid adenomyoma) from endometrial carcinoma invading the myometrium.
    Ohishi Y; Kaku T; Kobayashi H; Aishima S; Umekita Y; Wake N; Tsuneyoshi M
    Hum Pathol; 2008 Oct; 39(10):1446-53. PubMed ID: 18619643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chromosome abnormalities in human cancer].
    Salamanca-Gómez F
    Salud Publica Mex; 1995; 37(2):162-70. PubMed ID: 7618117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma.
    Sasaki H; Nishii H; Takahashi H; Tada A; Furusato M; Terashima Y; Siegal GP; Parker SL; Kohler MF; Berchuck A
    Cancer Res; 1993 Apr; 53(8):1906-10. PubMed ID: 8467512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.